Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus
about
Influenza virus antigenic variation, host antibody production and new approach to control epidemicsPhase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteersDiscordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza virusesImmunologic correlates of protection against rotavirus challenge after intramuscular immunization of miceInfluenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza VaccinesChimeric virus-like particles containing influenza HA antigen and GPI-CCL28 induce long-lasting mucosal immunity against H3N2 virusesMolecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza virusesInfluenza H1N1pdm-specific maternal antibodies offer limited protection against wild-type virus replication and influence influenza vaccination in ferretsT cell-mediated host immune defenses in the lungMechanisms of GII.4 norovirus persistence in human populationsAdenovirus-vectored drug-vaccine duo as a rapid-response tool for conferring seamless protection against influenzaHumoral and cell-mediated immunity to pandemic H1N1 influenza in a Canadian cohort one year post-pandemic: implications for vaccinationInfluenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferretsA miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigensLow seroprevalent species D adenovirus vectors as influenza vaccines.Immunologic consequences of chemotherapy for ovarian cancer: impaired responses to the influenza vaccineAntigen sparing and enhanced protection using a novel rOv-ASP-1 adjuvant in aqueous formulation with influenza vaccines.African green monkeys recapitulate the clinical experience with replication of live attenuated pandemic influenza virus vaccine candidates.Innate immune sensing and response to influenza.Hemagglutination inhibiting antibodies and protection against seasonal and pandemic influenza infectionInfluenza vaccines: a moving interdisciplinary field.Distinct patterns of B-cell activation and priming by natural influenza virus infection versus inactivated influenza vaccination.Development of stable influenza vaccine powder formulations: challenges and possibilitiesSeasonal influenza vaccination is the strongest correlate of cross-reactive antibody responses in migratory bird handlers.A review of the changes to the licensing of influenza vaccines in Europe.Influenza vaccines: from surveillance through production to protection.Flexible label-free quantitative assay for antibodies to influenza virus hemagglutininsInfluenza A virus infection kinetics: quantitative data and models.Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin.The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine.Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine.Heightened adaptive immune responses following vaccination with a temperature-sensitive, live-attenuated influenza virus compared to adjuvanted, whole-inactivated virus in pigs.Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice.A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges.Can immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses?Influence of prior influenza vaccination on antibody and B-cell responses.Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers.Oral retinyl palmitate or retinoic acid corrects mucosal IgA responses toward an intranasal influenza virus vaccine in vitamin A deficient mice.Role of immunoglobulin A in protection against reovirus entry into Murine Peyer's patches
P2860
Q21245119-62FB8662-AE44-49A0-BF98-84E10A3FB2AEQ24545856-ED94E811-C4F1-40B2-B8F2-E0AAAFD7339FQ24615003-69B42A77-9804-42EE-8A3B-31DFA2C0928CQ24671649-AACBE911-2A90-43EB-B7C1-7DF9D1AA7031Q26783844-80E1E00A-C5CE-4574-BF55-78DC9FB1E009Q28365124-4C4943AB-0D7C-4B49-B356-F28F3051AFECQ28387782-0B6A5DB4-F7B3-48E3-8437-31D879961C65Q28395364-FE3E6223-C2E3-4BEE-9666-88278761217FQ28395374-1BD38E4C-C20B-45C8-97C2-D48EF85D1348Q28472177-95C652F2-889E-47DE-B628-88414A2EAEA7Q28479491-E349D336-3604-425C-AA0E-ED2F48FBEA69Q28742312-3BBC5E44-73FC-4ED8-827A-3EE6D005254DQ28742787-91587998-D574-414D-9C19-8CBD054AAD9CQ28830491-59A82B40-CF87-477B-94D1-79A065503068Q30353263-EC8F38FC-1691-4A45-87F6-5F6A94F4BD3CQ30353632-BEBEE7E3-B041-4F3C-9043-BEEECD8ED9E4Q30360768-31C97672-BF8D-4A97-AD34-BFECC561A01FQ30362332-AFD670B3-4ED8-4A69-ADF0-6861D2632B69Q30365302-9AC6F44B-C4E4-4674-AFBF-5E49642E61ADQ30366832-A384A33A-843E-4837-8150-3D2E47E545ACQ30367695-134D9924-01A9-4CDB-908D-8B50FD9D5874Q30368005-636FC8A2-15D7-4474-8089-0CBFF33937B5Q30368221-793F890D-1C41-4FD1-8415-4DABBF395449Q30369530-94D62479-B3B3-4E28-A957-1DECACD749A6Q30379967-1D06939E-4CFE-4042-8D26-DB8B87D6EA50Q30385118-7BC10D03-73D2-420C-A1AB-638627852BA9Q30391853-E166C69A-7B21-4911-8E5F-F93E782BAA90Q30398031-A8C60660-43A4-4474-A23A-69CEE6415E2DQ30398228-848DEA73-5742-4E8D-9E47-2D46B6AD0DAEQ30401519-0E95AB48-5FB4-49FD-BA41-3AEA58E10688Q30404699-9801B643-1FEF-4896-9AD4-A13C4D5E5A60Q30412266-206ED1E7-7AF3-4D3E-8891-A32C62A5FFBAQ30419702-C7E62F72-9C5C-4524-80B2-FD8E2C82E9F9Q30422513-2A540DBC-59C3-4A87-88E4-277DE4B522B3Q30430275-D2A3EF49-F178-4671-B50E-6C8EB5368353Q33273605-4AEC71B9-BEEB-41F3-9A1E-0558E09E0A63Q33361605-B57B25EC-0C61-4B57-81B8-F49D5E36DD3FQ33650384-FC9C7990-4FA0-429F-8C87-44C881F1E6BBQ33725040-D4ABB55D-CC5A-46ED-85BE-378319F04F2EQ33848974-BB1E68BD-DE9B-40AB-8C7F-6C84317FC970
P2860
Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 1986
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Serum and nasal wash antibodie ...... th influenza A wild-type virus
@en
Serum and nasal wash antibodie ...... h influenza A wild-type virus.
@nl
type
label
Serum and nasal wash antibodie ...... th influenza A wild-type virus
@en
Serum and nasal wash antibodie ...... h influenza A wild-type virus.
@nl
prefLabel
Serum and nasal wash antibodie ...... th influenza A wild-type virus
@en
Serum and nasal wash antibodie ...... h influenza A wild-type virus.
@nl
P2093
P2860
P1476
Serum and nasal wash antibodie ...... th influenza A wild-type virus
@en
P2093
B R Murphy
E L Tierney
M L Clements
P2860
P304
P407
P577
1986-07-01T00:00:00Z